CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study

NCT04552704 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Terminated early by the Sponsor due to business reason.

Conditions

Advanced Malignant Solid Neoplasm

Interventions

BIOLOGICAL: CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc
DRUG: Placebo Administration

Sponsor

Tianhong Li

Collaborators

[object Object]
[object Object]